EMA issues guidance for global development of antimicrobial medicines

  27 May 2022

The European Medicines Agency (EMA) has published its final revised guideline on the evaluation of human medicines for the treatment of bacterial infections. The guidance forms part of EMA’s efforts to support a global approach to the development of new antimicrobial medicines.

Antimicrobial resistance (AMR) – the ability of microorganisms to resist antimicrobial treatments, especially antibiotics – has a direct impact on the health of people and animals. In the European Union (EU) alone, it is responsible for an estimated 33,000 deaths per year. Its effects are also felt on a financial level worldwide, with AMR estimated to cost the EU €1.5 billion per year in healthcare costs and productivity losses.

Author(s): European Pharmaceutical Review
Smart Innovations  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!